Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials.

ABSTRACT:

Background

Relebactam is a new inhibitor of class A and class C β-lactamases. The FDA has approved combining IMI/CS/REL to treat some infectious diseases. This study systematically reviews the efficacy and safety of IMI/CS/REL based on existing clinical trials so as to provide a reference for follow-up research.

Methods

Researchers comprehensively searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomised controlled trials published up to Mar 28, 2025, with "Imipenem/Cilastatin/Relebactam" or "IMI/CS/REL" as keywords, and screened the results according to the proposed exclusion and inclusion criteria. Data extraction was performed on the included randomized controlled trials (RCTs), while the day 28/30 all-cause mortality, clinical response rate, microb

SUBMITTER: Lei W 

PROVIDER: S-EPMC12465972 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature